Company intelligence / Profile preview

Zenopharm

New Orleans, Louisiana, United Stateszenopharm.com ↗
Ownership
Private
Employees
~10
Development stage
Other
01

Overview

Zenopharm is advancing ZB716, an oral selective estrogen receptor degrader designed to improve bioavailability over existing therapies like fulvestrant. Preclinical data show superior pharmacokinetics and efficacy in breast tumor models. The company has received SBIR funding to complete IND-enabling studies and has initiated a Phase I clinical trial supported by a $4 million investment. Their portfolio also includes boron-based prodrugs targeting breast cancer and novel agents inhibiting tumor angiogenesis[1][2][5][8].

Therapeutic areas
Oncology
Modalities
Oral selective estrogen receptor degraders (SERDs)Boron-based prodrugsSmall molecules with anti-metastasis and anti-tumor angiogenesis activity
Industry
Biotech
02

Partnerships

Avista Pharma Solutions for GMP manufacturing of API[5]Covance for nonclinical development plan implementation[5]Collaboration with Xavier University researchers at founding[1]

Beyond the preview

Go deeper on Zenopharm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zenopharm.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call